Product Details
| Alternative Name: | Hypoxia-inducible factor 1α, ARNT-interacting protein |
| |
| Clone: | Halpha111a |
| |
| Host: | Mouse |
| |
| Isotype: | IgG2a |
| |
| Immunogen: | Recombinant human HIF-1α. |
| |
| UniProt ID: | Q16665 |
| |
| Source: | Purified from hybridoma tissue culture supernatant. |
| |
| Species reactivity: | Human
|
| |
| Applications: | IHC, WB
|
| |
| Recommended Dilutions/Conditions: | Western Blot (4µg/ml)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects a band of ~120kDa by Western blot. |
| |
| Purity Detail: | Protein G affinity purified. |
| |
| Formulation: | Liquid. In PBS, pH 7.2, containing 50% glycerol and 0.09% sodium azide. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Hypoxia inducible factor-1 (HIF-1) is a transcriptional complex which regulates systemic, local and intracellular homeostatic responses elicited by hypoxia. HIF-1 is a heterodimer of HIF-1alpha and HIF-1beta. HIF-1beta is constitutively expressed and serves as a dimerization partner for several other transcription factors, while HIF-1alpha and the closely related HIF-2 are unique to HIF-1 and their expression is tightly regulated by cellular oxygen concentration. HIF-1 regulates a diverse group of genes, including erythropoietin, VEGF, glucose transporters, heme oxygenase, and NOS. |
| |
| Technical Info/Product Notes: | Recommended by the Human Protein Atlas Organization for IHC (Ensembl No. ENSG00000100644). |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Western blot analysis of HIF-1α, mAb (Hα111a) (Prod. No. ADI-OSA-602): Lane 1: HeLa Cell Lysate (Prod. No. ADI-LYC-HL100), Lane 2: HeLa+CoCl2 Cell Lysate.
Please mouse over
Product Literature References
Potential role of CXCR4 in trastuzumab resistance in breast cancer patients: R.M. Kotb, et al.; Biochim. Biophys. Acta Mol. Basis Dis.
1868, 166520 (2022),
Abstract;
Metabolic characteristics distinguishing intrahepatic cholangiocarcinoma: a negative pilot study of 18F-fluorocholine PET/CT clarified by transcriptomic analysis: S.A. Kwee, et al.; Am. J. Nucl. Med. Mol. Imaging
6, 73 (2016),
Application(s): Immunohistochemistry,
Abstract;
Full Text
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition: K.P. Ng, et al.; Blood
123, 3316 (2014),
Application(s): Immunohistochemistry,
Abstract;
Related Products
